Tuberculosis remains one of the most consequential infectious diseases in human history, yet its trajectory over the past three decades has been uneven — shaped by HIV co-infection, drug resistance, and fragile health systems. Understanding exactly where progress has been made, and where it has stalled, is now more urgent than ever as global health funding faces significant contraction precisely when sustained investment is most critical.
This Global Burden of Disease 2023 analysis quantified TB mortality, morbidity, and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 through 2023, stratifying outcomes by HIV status and drug-resistance profile. Using the Cause of Death Ensemble model alongside DisMod-MR 2.1 — tools that integrate vital registration records, surveillance data, verbal autopsy, and minimally invasive tissue sampling — the researchers produced granular age- and sex-disaggregated estimates of incidence, prevalence, and mortality. A comparative risk assessment framework further attributed a proportion of the burden to modifiable risk factors: alcohol use, tobacco smoking, and elevated fasting plasma glucose. The analysis benchmarks progress against the WHO End TB Strategy targets — a 95% reduction in deaths and 90% reduction in incidence between 2015 and 2035 — revealing the gap between ambition and current trajectory.
This is among the most methodologically rigorous longitudinal assessments of TB burden ever conducted, and its findings carry significant implications. The MDR-TB stratification is particularly telling: drug-resistant strains now represent a growing share of the global burden in regions with historically weak antibiotic stewardship. The inclusion of HIV co-infection as an independent stratifier highlights persisting syndemic risk in sub-Saharan Africa, where TB remains a leading AIDS-defining illness. The risk factor attribution to alcohol, smoking, and dysglycemia is noteworthy — it frames TB not merely as an infectious disease challenge but as one entangled with non-communicable disease epidemiology, potentially broadening the intervention landscape. As a systematic analysis rather than a randomized trial, causal inference remains limited, and country-level data quality varies considerably. Still, for policy prioritization and resource allocation, GBD analyses of this scale are arguably the most actionable epidemiological instruments available.